Furthermore, a recent study showed a BACE1‐dependent insulin receptor (IR) reduction in the liver of AD patients, which concluded that IRs are an additional novel substrate for BACE1, highlighting the role of BACE1 in type II diabetes and other metabolic disorders which are associated with underlying chronic insulin resistance (Meakin et al., 2018). The gene discussed is BACE1; the disease is metabolic disease.